tetano
Editor, Senior Moderator
Nat Commun
. 2025 Mar 26;16(1):2969.
doi: 10.1038/s41467-025-58327-y. Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China
Siyue Jia[SUP] #[/SUP][SUP] 1 [/SUP], Yuanbao Liu[SUP] #[/SUP][SUP] 1 [/SUP], Qian He[SUP] #[/SUP][SUP] 2 [/SUP], Hongxing Pan[SUP] 1 [/SUP], Zhenglun Liang[SUP] 2 [/SUP], Juan Zhou[SUP] 3 [/SUP], Yingzi Pan[SUP] 4 [/SUP], Sheng Liu[SUP] 5 [/SUP], Jingjing Wu[SUP] 6 [/SUP], Kun Yang[SUP] 7 [/SUP], Xuanxuan Zhang[SUP] 2 [/SUP], Yang Zhao[SUP] 8 [/SUP], Simin Li[SUP] 9 [/SUP], Lei Zhang[SUP] 1 [/SUP], Li Chen[SUP] 9 [/SUP], Aihua Yao[SUP] 9 [/SUP], Mengyi Lu[SUP] 8 [/SUP], Fengcai Zhu[SUP] 10 11 12 [/SUP], Qunying Mao[SUP] 13 [/SUP], Jingxin Li[SUP] 14 15 16 [/SUP]
Affiliations
We conducted a multicenter, partially randomized, platform trial to assess the effectiveness of a booster dose of an aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) in Chinese adults (NCT05855408). Between May 23, 2023, and August 28, 2023, 4089 eligible participants were equally randomized to receive either a booster dose of aerosolized Ad5-nCoV via oral inhalation at 0.1 mL (IH Ad5-nCoV, n = 2039) or an intramuscular injection of Ad5-nCoV at 0.5 mL (IM Ad5-nCoV, n = 2050). Additionally, 2008 participants who declined the booster but consented to participate in COVID-19 surveillance were enrolled in the control group. All participants were monitored for symptomatic COVID-19 over a six-month surveillance period for the primary outcome. From 14 days after the vaccination, 14 (15/1000 person-years), 19 (20/1000 person-years), and 34 (37/1000 person-years) COVID-19 cases were confirmed in the IH Ad5-nCoV group, the IM Ad5-nCoV group, and the control group, respectively, which resulted in an adjusted effectiveness of 52.3% (95% CI 10.4 to 74.6) for IH Ad5-nCoV and 37.2% (95% CI -11.2 to 64.5) for IM Ad5-nCoV. The IH Ad5-nCoV booster was associated with a lower incidence of symptomatic COVID-19, but there is no solid evidence that IH Ad5-nCoV was more effective than IM Ad5-nCoV.
. 2025 Mar 26;16(1):2969.
doi: 10.1038/s41467-025-58327-y. Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China
Siyue Jia[SUP] #[/SUP][SUP] 1 [/SUP], Yuanbao Liu[SUP] #[/SUP][SUP] 1 [/SUP], Qian He[SUP] #[/SUP][SUP] 2 [/SUP], Hongxing Pan[SUP] 1 [/SUP], Zhenglun Liang[SUP] 2 [/SUP], Juan Zhou[SUP] 3 [/SUP], Yingzi Pan[SUP] 4 [/SUP], Sheng Liu[SUP] 5 [/SUP], Jingjing Wu[SUP] 6 [/SUP], Kun Yang[SUP] 7 [/SUP], Xuanxuan Zhang[SUP] 2 [/SUP], Yang Zhao[SUP] 8 [/SUP], Simin Li[SUP] 9 [/SUP], Lei Zhang[SUP] 1 [/SUP], Li Chen[SUP] 9 [/SUP], Aihua Yao[SUP] 9 [/SUP], Mengyi Lu[SUP] 8 [/SUP], Fengcai Zhu[SUP] 10 11 12 [/SUP], Qunying Mao[SUP] 13 [/SUP], Jingxin Li[SUP] 14 15 16 [/SUP]
Affiliations
- PMID: 40140382
- DOI: 10.1038/s41467-025-58327-y
We conducted a multicenter, partially randomized, platform trial to assess the effectiveness of a booster dose of an aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) in Chinese adults (NCT05855408). Between May 23, 2023, and August 28, 2023, 4089 eligible participants were equally randomized to receive either a booster dose of aerosolized Ad5-nCoV via oral inhalation at 0.1 mL (IH Ad5-nCoV, n = 2039) or an intramuscular injection of Ad5-nCoV at 0.5 mL (IM Ad5-nCoV, n = 2050). Additionally, 2008 participants who declined the booster but consented to participate in COVID-19 surveillance were enrolled in the control group. All participants were monitored for symptomatic COVID-19 over a six-month surveillance period for the primary outcome. From 14 days after the vaccination, 14 (15/1000 person-years), 19 (20/1000 person-years), and 34 (37/1000 person-years) COVID-19 cases were confirmed in the IH Ad5-nCoV group, the IM Ad5-nCoV group, and the control group, respectively, which resulted in an adjusted effectiveness of 52.3% (95% CI 10.4 to 74.6) for IH Ad5-nCoV and 37.2% (95% CI -11.2 to 64.5) for IM Ad5-nCoV. The IH Ad5-nCoV booster was associated with a lower incidence of symptomatic COVID-19, but there is no solid evidence that IH Ad5-nCoV was more effective than IM Ad5-nCoV.